Evidence map›Paper›PMID 34863438›Full record

ArticleJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2021

Hormone exposure and its suppressive effect on risk of high-grade gliomas among patients with breast cancer.

Carlos A Lopez-Garcia, Victor Lopez-Rivera, Antonio Dono, Sergio Salazar-Marioni, Jorge E Novo, Sunil A Sheth, Leomar Y Ballester, Yoshua Esquenazi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Carlos A Lopez-GarciaDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Victor Lopez-RiveraDepartment of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Antonio DonoVivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA.
Sergio Salazar-MarioniDepartment of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Jorge E NovoDepartment of Pathology and Laboratory Medicine Northwestern, Chicago, IL, USA.
Sunil A ShethDepartment of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Leomar Y BallesterDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA; Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA; Memorial Hermann Hospital, Houston, TX, USA. Electronic address: Leomar.Y.Ballester@uth.tmc.edu.
Yoshua EsquenaziVivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA; Memorial Hermann Hospital, Houston, TX, USA; Center of Precision Health, School of Biomedical Informatics, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: Yoshua.EsquenaziLevy@uth.tmc.edu.
The University of Texas Health Science Center at Houston · USMemorial Hermann · USNorthwestern Medicine · US

Funding

Development and Validation of a CSF Liquid Biopsy for Molecular Characterization and Monitoring of Patients with Central Nervous System TumorsK08CA241651 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BALLESTER, LEOMAR Y · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA241651
6 · The paper itself

Abstract

backgroundPrior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacterized.

methodsUsing the SEER 18 registries (2000-2017), we examined the temporal trend of the incidence of HGGs and BC. The standardized incidence ratio was calculated to assess the risk of subsequent HGG in BC patients.

resultsDuring the study period, the incidence of BC and HGGs remained comparable for men and women. Among 976,134 patients with BC, we found a decreased incidence of HGGs in females, but not in males. Female BC patients with hormone receptor-positive disease were at a lower risk of developing glioblastoma and anaplastic astrocytoma.

conclusionOur study findings allude to the protective role of hormone exposure in the development of HGGs, which may lead to the development of therapies targeting hormonal pathways.

Indexed as

AstrocytomaBreast NeoplasmsGlioblastomaGliomaFemaleHormonesHumansMaleHormonesAnaplastic astrocytomaBreast cancerGlioblastomaHigh-grade gliomaHormone exposureSEER

Identifiers

PMID34863438
PMCPMC9338691
OpenAlexW3209101483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.